Low-molecular-weight heparin (reviparin) reduces the incidence of femoropopliteal in-stent stenosis : Preliminary results of an ongoing study
To examine the efficacy of the low-molecular-weight heparin, reviparin, for prevention of femoropopliteal stent restenosis. Forty-two patients who had implantation of flexible tantalum stents for the treatment of stenosis (n = 24) or occlusion (n = 18) of the femoral (n = 27) or popliteal (n = 15) a...
Saved in:
Published in | Cardiovascular and interventional radiology Vol. 21; no. 5; pp. 375 - 379 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
Heidelberg
Springer
01.09.1998
Berlin Springer Nature B.V |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | To examine the efficacy of the low-molecular-weight heparin, reviparin, for prevention of femoropopliteal stent restenosis.
Forty-two patients who had implantation of flexible tantalum stents for the treatment of stenosis (n = 24) or occlusion (n = 18) of the femoral (n = 27) or popliteal (n = 15) arteries were included in this study protocol. An intraarterial bolus of 5000 IU heparin was given before percutaneous transluminal angioplasty (PTA), and in the case of stent implantation due to unsuccessful PTA, an additional dose of reviparin (3500 anti-factor Xa IU) was given. Postprocedurally, 10,500 anti-factor Xa IU of reviparin were administered intravenously over 24 hr, followed by 3500 anti-factor Xa IU subcutaneously twice a day for 23 days. Oral aspirin (100 mg/day) was prescribed for the long term. Follow-up criteria (maximum follow-up 37 months) were clinical symptoms, Doppler ankle arm indices, color and duplex sonography, and angiography for suspicion of restenosis.
Early stent thromboses were not observed. Overall primary patency rate (PPR) was 88% +/- 6.0% (1 year) and 74% +/- 10.1% (2 years). Major hemorrhagic complications have not occurred.
Reviparin administered in a high dose over a period of 24 days is a safe medication regimen and provides excellent patency rates after stent implantation. |
---|---|
AbstractList | PURPOSETo examine the efficacy of the low-molecular-weight heparin, reviparin, for prevention of femoropopliteal stent restenosis.METHODSForty-two patients who had implantation of flexible tantalum stents for the treatment of stenosis (n = 24) or occlusion (n = 18) of the femoral (n = 27) or popliteal (n = 15) arteries were included in this study protocol. An intraarterial bolus of 5000 IU heparin was given before percutaneous transluminal angioplasty (PTA), and in the case of stent implantation due to unsuccessful PTA, an additional dose of reviparin (3500 anti-factor Xa IU) was given. Postprocedurally, 10,500 anti-factor Xa IU of reviparin were administered intravenously over 24 hr, followed by 3500 anti-factor Xa IU subcutaneously twice a day for 23 days. Oral aspirin (100 mg/day) was prescribed for the long term. Follow-up criteria (maximum follow-up 37 months) were clinical symptoms, Doppler ankle arm indices, color and duplex sonography, and angiography for suspicion of restenosis.RESULTSEarly stent thromboses were not observed. Overall primary patency rate (PPR) was 88% +/- 6.0% (1 year) and 74% +/- 10.1% (2 years). Major hemorrhagic complications have not occurred.CONCLUSIONReviparin administered in a high dose over a period of 24 days is a safe medication regimen and provides excellent patency rates after stent implantation. Purpose: To examine the efficacy of the low-molecular-weight heparin, reviparin, for prevention of femoropopliteal stent restenosis. Methods: Forty-two patients who had implantation of flexible tantalum stents for the treatment of stenosis (n= 24) or occlusion (n= 18) of the femoral (n= 27) or popliteal (n= 15) arteries were included in this study protocol. An intraarterial bolus of 5000 IU heparin was given before percutaneous transluminal angioplasty (PTA), and in the case of stent implantation due to unsuccessful PTA, an additional dose of reviparin (3500 anti-factor Xa IU) was given. Postprocedurally, 10,500 anti-factor Xa IU of reviparin were administered intravenously over 24 hr, followed by 3500 anti-factor Xa IU subcutaneously twice a day for 23 days. Oral aspirin (100 mg/day) was prescribed for the long term. Follow-up criteria (maximum follow-up 37 months) were clinical symptoms, Doppler ankle arm indices, color and duplex sonography, and angiography for suspicion of restenosis. Results: Early stent thromboses were not observed. Overall primary patency rate (PPR) was 88% {+-} 6.0% (1 year) and 74% {+-} 10.1% (2 years). Major hemorrhagic complications have not occurred. Conclusion: Reviparin administered in a high dose over a period of 24 days is a safe medication regimen and provides excellent patency rates after stent implantation. Purpose: To examine the efficacy of the low-molecular-weight heparin, reviparin, for prevention of femoropopliteal stent restenosis.Methods: Forty-two patients who had implantation of flexible tantalum stents for the treatment of stenosis (n=24) or occlusion (n=18) of the femoral (n=27) or popliteal (n=15) arteries were included in this study protocol. An intraarterial bolus of 5000 IU heparin was given before percutaneous transluminal angioplasty (PTA), and in the case of stent implantation due to unsuccessful PTA, an additional dose of reviparin (3500 anti-factor Xa IU) was given. Postprocedurally, 10,500 anti-factor Xa IU of reviparin were administered intravenously over 24 hr, followed by 3500 anti-factor Xa IU subcutaneously twice a day for 23 days. Oral aspirin (100 mg/day) was prescribed for the long term. Follow-up criteria (maximum follow-up 37 months) were clinical symptoms, Doppler ankle arm indices, color and duplex sonography, and angiography for suspicion of restenosis.Results: Early stent thromboses were not observed. Overall primary patency rate (PPR) was 88%±6.0% (1 year) and 74%±10.1% (2 years). Major hemorrhagic complications have not occurred.Conclusion: Reviparin administered in a high dose over a period of 24 days is a safe medication regimen and provides excellent patency rates after stent implantation. To examine the efficacy of the low-molecular-weight heparin, reviparin, for prevention of femoropopliteal stent restenosis. Forty-two patients who had implantation of flexible tantalum stents for the treatment of stenosis (n = 24) or occlusion (n = 18) of the femoral (n = 27) or popliteal (n = 15) arteries were included in this study protocol. An intraarterial bolus of 5000 IU heparin was given before percutaneous transluminal angioplasty (PTA), and in the case of stent implantation due to unsuccessful PTA, an additional dose of reviparin (3500 anti-factor Xa IU) was given. Postprocedurally, 10,500 anti-factor Xa IU of reviparin were administered intravenously over 24 hr, followed by 3500 anti-factor Xa IU subcutaneously twice a day for 23 days. Oral aspirin (100 mg/day) was prescribed for the long term. Follow-up criteria (maximum follow-up 37 months) were clinical symptoms, Doppler ankle arm indices, color and duplex sonography, and angiography for suspicion of restenosis. Early stent thromboses were not observed. Overall primary patency rate (PPR) was 88% +/- 6.0% (1 year) and 74% +/- 10.1% (2 years). Major hemorrhagic complications have not occurred. Reviparin administered in a high dose over a period of 24 days is a safe medication regimen and provides excellent patency rates after stent implantation. |
Author | VETTER, S BOOS, I. B. L STRECKER, E.-P. K GÖTTMANN, D |
Author_xml | – sequence: 1 givenname: E.-P. K surname: STRECKER fullname: STRECKER, E.-P. K organization: Department of Radiology, Diakonissen Hospital, Diakonissenstrasse 28, 76199 Karlsruhe, Germany – sequence: 2 givenname: D surname: GÖTTMANN fullname: GÖTTMANN, D organization: Department of Radiology, Diakonissen Hospital, Diakonissenstrasse 28, 76199 Karlsruhe, Germany – sequence: 3 givenname: I. B. L surname: BOOS fullname: BOOS, I. B. L organization: Department of Radiology, Diakonissen Hospital, Diakonissenstrasse 28, 76199 Karlsruhe, Germany – sequence: 4 givenname: S surname: VETTER fullname: VETTER, S organization: Department of Radiology, Diakonissen Hospital, Diakonissenstrasse 28, 76199 Karlsruhe, Germany |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2433563$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/9853142$$D View this record in MEDLINE/PubMed https://www.osti.gov/biblio/21080370$$D View this record in Osti.gov |
BookMark | eNpdkU2LFDEQhoOsrLOrR49CUBE9tFY-Oun2JotfMKAHBW9NJl09k6U7aZO0y_4I_7NpZ1jQSyrwPvVSVe8FOfPBIyGPGbxmAPpNAuAa2raURtwjGyYFr6BRP87IBpiWFatr9oBcpHQNwOqG1-fkvG1qwSTfkN_bcFNNYUS7jCZWN-j2h0wPOJvoPH0Z8Zf7-31FI_aLxUTzAanz1vXoLdIw0AGnEMMc5tFlNGMRq5TRZ7q-IblE39KvEUc3OW_ibTFKy5jT2mo8DX4fnN8XeOlvH5L7gxkTPjrVS_L9w_tvV5-q7ZePn6_ebSsrNM9VDxoYE9rypmaC962QUukdaNXAYNRukAZ104p20EoYpVAJZaAFBnXNpdbikjw7-oaUXZdsGdwebPAebe44gwaEhkK9OFJzDD8XTLmbXLI4jsZjWFK3DqG0rgv49D_wOizRlw06zRvJhGQrVB0hG0NKEYdujm4qB-kYdGuS3T9JFv7JyXTZTdjf0afoiv78pJtkzThEU0JJdxiXQtRKiD8iMaaH |
CODEN | CAIRDG |
CitedBy_id | crossref_primary_10_1024_0301_1526_a000834 crossref_primary_10_1016_j_jvs_2006_07_044 crossref_primary_10_1148_radiol_2221010268 crossref_primary_10_1177_1358836X0000500409 crossref_primary_10_1016_S1051_0443_00_70167_9 crossref_primary_10_1002_ccd_10211 crossref_primary_10_1177_1076029613492877 crossref_primary_10_1007_s00772_006_0481_0 crossref_primary_10_1007_s00117_009_1916_x crossref_primary_10_1007_s11883_004_0103_9 crossref_primary_10_1016_S1051_0443_01_70027_9 crossref_primary_10_1177_107602960200800405 crossref_primary_10_3109_13645709909153152 |
Cites_doi | 10.1002/jcp.1041290103 10.1148/radiology.184.3.1509075 10.1016/S0735-1097(96)00343-9 10.1016/0735-1097(91)90947-8 10.1016/S1051-0443(95)71198-8 10.1016/S0268-9499(05)80010-4 10.1038/265625a0 10.1583/1074-6218(1996)003<0369:CEWANN>2.0.CO;2 10.1016/0002-8703(89)90612-1 10.1161/01.CIR.91.6.1676 10.1007/BF02116062 10.1161/01.CIR.85.4.1548 10.1007/BF01907681 10.1148/radiology.205.2.9356617 10.1056/NEJM198602203140806 10.1016/S1051-0443(91)72275-6 10.1161/01.RES.67.3.651 10.1161/01.CIR.94.1.35 10.1148/radiology.197.1.7568818 |
ContentType | Journal Article |
Copyright | 1998 INIST-CNRS Springer-Verlag 1998. |
Copyright_xml | – notice: 1998 INIST-CNRS – notice: Springer-Verlag 1998. |
DBID | IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 3V. 7RV 7TO 7X7 7XB 88E 8AO 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH H94 K9. KB0 M0S M1P NAPCQ PQEST PQQKQ PQUKI PRINS 7X8 OTOTI |
DOI | 10.1007/s002709900283 |
DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Central (Corporate) Nursing & Allied Health Database (ProQuest) Oncogenes and Growth Factors Abstracts Health & Medical Collection (Proquest) ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central ProQuest Central ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Health & Medical Collection (Alumni Edition) Medical Database Nursing & Allied Health Premium ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic OSTI.GOV |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Oncogenes and Growth Factors Abstracts ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Pharma Collection ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central Nursing & Allied Health Premium ProQuest Health & Medical Complete Health Research Premium Collection ProQuest Medical Library ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) AIDS and Cancer Research Abstracts ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest Medical Library (Alumni) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic Oncogenes and Growth Factors Abstracts MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1432-086X |
EndPage | 379 |
ExternalDocumentID | 21080370 2092817951 10_1007_s002709900283 9853142 2433563 |
Genre | Clinical Trial Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- -53 -5E -5G -BR -EM -Y2 -~C .86 .GJ .VR 04C 06C 06D 0R~ 0VY 1N0 1SB 2.D 203 28- 29B 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2P1 2VQ 2~H 30V 36B 3V. 4.4 406 408 409 40D 40E 53G 5GY 5QI 5RE 5VS 67Z 6NX 6PF 78A 7RV 7X7 88E 8AO 8FI 8FJ 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AABYN AAFGU AAHNG AAIAL AAJKR AAKSU AANXM AANZL AAPBV AARHV AARTL AATNV AATVU AAUYE AAWCG AAWTL AAYFA AAYIU AAYQN AAYTO ABBBX ABBXA ABDZT ABECU ABFGW ABFTV ABHLI ABHQN ABIPD ABJOX ABKAS ABKCH ABKTR ABLJU ABMNI ABMQK ABNWP ABOCM ABPLI ABQBU ABSXP ABTEG ABTKH ABTMW ABULA ABUWG ABWNU ABXPI ACBMV ACBRV ACBXY ACBYP ACGFS ACHSB ACHVE ACHXU ACIGE ACIPQ ACKNC ACMDZ ACMLO ACOKC ACOMO ACPRK ACTTH ACUDM ACVWB ACWMK ADBBV ADHHG ADHIR ADINQ ADKNI ADKPE ADMDM ADOXG ADRFC ADTPH ADURQ ADYFF ADZKW AEBTG AEEQQ AEFIE AEFTE AEGAL AEGNC AEJHL AEJRE AEKMD AENEX AEOHA AEPYU AESKC AESTI AETLH AEVLU AEVTX AEXYK AFAFS AFEXP AFJLC AFKRA AFLOW AFNRJ AFQWF AFRAH AFWTZ AFZKB AGAYW AGDGC AGGBP AGGDS AGJBK AGKHE AGMZJ AGQMX AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHKAY AHMBA AHSBF AHYZX AIAKS AIIXL AILAN AIMYW AITGF AJBLW AJDOV AJRNO AJZVZ AKMHD AKQUC ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AMYQR AOCGG ARMRJ ASPBG AVWKF AXYYD AZFZN B-. BA0 BBWZM BDATZ BENPR BGNMA BKEYQ BPHCQ BVXVI CAG CCPQU COF CS3 CSCUP DDRTE DL5 DNIVK DPUIP DU5 EBLON EBS EIOEI EJD EMB EMOBN EN4 ESBYG EX3 F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GQ8 GRRUI GXS H13 HF~ HG5 HG6 HMJXF HQYDN HRMNR HZ~ I09 IHE IJ- IKXTQ IMOTQ IQODW IWAJR IXC IXD IXE IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KDC KOV KOW KPH LAS LLZTM M1P M4Y MA- N2Q N9A NAPCQ NB0 NDZJH NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OAM OVD P19 P2P P9S PF0 PQQKQ PROAC PSQYO PT4 PT5 Q2X QOK QOR QOS R4E R89 R9I RHV RIG RNI ROL RPX RRX RSV RZK S16 S1Z S26 S27 S28 S37 S3B SAP SCLPG SDE SDH SDM SHX SISQX SJYHP SMD SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZ9 SZN T13 T16 TEORI TSG TSK TSV TT1 TUC U2A U9L UG4 UKHRP UNUBA UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WJK WK8 WOW YLTOR Z45 Z7U Z7V Z7X Z7Y Z82 Z83 Z87 Z8O Z8P Z8S Z8V Z8W Z91 ZGI ZMTXR ZOVNA ~EX AAEOY AAJBT AASML ABAKF ABJNI ACAOD ACDTI ACZOJ AEFQL AEMSY AFBBN AGQEE AGRTI AIGIU CGR CUY CVF ECM EIF HMCUK HVGLF NPM AACDK AAYXX AJOOF ALIPV CITATION 7TO 7XB 8FK H94 K9. PQEST PQUKI PRINS 7X8 OTOTI |
ID | FETCH-LOGICAL-c372t-d0701137c285132d934467b07680fa6bf4ae78939f763a66e636a090105524773 |
IEDL.DBID | BENPR |
ISSN | 0174-1551 |
IngestDate | Fri May 19 00:39:02 EDT 2023 Fri Aug 16 12:13:51 EDT 2024 Wed Sep 25 03:00:07 EDT 2024 Thu Sep 12 17:16:44 EDT 2024 Thu May 23 23:02:10 EDT 2024 Sun Oct 29 17:09:43 EDT 2023 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 5 |
Keywords | Human Reviparin sodium Endoprosthesis Femoral artery Treatment efficiency Instrumentation therapy Cardiovascular disease Low molecular weight heparin Popliteal artery Anticoagulant Stent Incidence Vascular disease Prevention Restenosis Chemotherapy Treatment Complication Heparin High dose |
Language | English |
License | CC BY 4.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c372t-d0701137c285132d934467b07680fa6bf4ae78939f763a66e636a090105524773 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
PMID | 9853142 |
PQID | 728413415 |
PQPubID | 54058 |
PageCount | 5 |
ParticipantIDs | osti_scitechconnect_21080370 proquest_miscellaneous_70116775 proquest_journals_728413415 crossref_primary_10_1007_s002709900283 pubmed_primary_9853142 pascalfrancis_primary_2433563 |
PublicationCentury | 1900 |
PublicationDate | 1998-09-01 |
PublicationDateYYYYMMDD | 1998-09-01 |
PublicationDate_xml | – month: 09 year: 1998 text: 1998-09-01 day: 01 |
PublicationDecade | 1990 |
PublicationPlace | Heidelberg Berlin |
PublicationPlace_xml | – name: Berlin – name: Heidelberg – name: United States – name: Vienna |
PublicationTitle | Cardiovascular and interventional radiology |
PublicationTitleAlternate | Cardiovasc Intervent Radiol |
PublicationYear | 1998 |
Publisher | Springer Springer Nature B.V |
Publisher_xml | – name: Springer – name: Springer Nature B.V |
References | P Chatelard (2429_CR7) 1996; 37 AW Clowes (2429_CR14) 1977; 265 M Henry (2429_CR6) 1995; 196 KM Schmid (2429_CR22) 1993; 19 T Schmidt (2429_CR19) 1990; 68 2429_CR1 R Ross (2429_CR11) 1986; 314 H Hämmerle (2429_CR15) 1991; 20 M Henry (2429_CR25) 1996; 3 2429_CR20 MR Sapoval (2429_CR24) 1992; 184 CG Reilly (2429_CR18) 1986; 129 E Starck (2429_CR26) 1996; 20 EP Strecker (2429_CR9) 1997; 205 2429_CR23 D Roth (2429_CR21) 1992; 35 A Colombo (2429_CR28) 1995; 91 KR Karsch (2429_CR4) 1996; 28 CC Haudenschild (2429_CR10) 1995; 9 RB Rutherford (2429_CR5) 1991; 2 E Betz (2429_CR2) 1979; 74 H Hanke (2429_CR13) 1990; 67 EC Martin (2429_CR8) 1995; 6 SG Ellis (2429_CR16) 1989; 117 2429_CR12 H Hanke (2429_CR3) 1992; 85 JW Currier (2429_CR17) 1991; 17 GS Mintz (2429_CR27) 1996; 94 |
References_xml | – volume: 129 start-page: 11 year: 1986 ident: 2429_CR18 publication-title: J Cell Physiol doi: 10.1002/jcp.1041290103 contributor: fullname: CG Reilly – ident: 2429_CR1 – volume: 184 start-page: 833 year: 1992 ident: 2429_CR24 publication-title: Radiology doi: 10.1148/radiology.184.3.1509075 contributor: fullname: MR Sapoval – volume: 28 start-page: 1437 year: 1996 ident: 2429_CR4 publication-title: J Am Coll Cardiol doi: 10.1016/S0735-1097(96)00343-9 contributor: fullname: KR Karsch – volume: 17 start-page: 118B year: 1991 ident: 2429_CR17 publication-title: J Am Coll Cardiol doi: 10.1016/0735-1097(91)90947-8 contributor: fullname: JW Currier – volume: 37 start-page: 67 issue: Suppl 1 year: 1996 ident: 2429_CR7 publication-title: J Cardiovasc Surg Torino contributor: fullname: P Chatelard – volume: 6 start-page: 843 year: 1995 ident: 2429_CR8 publication-title: J Vasc Interv Radiol doi: 10.1016/S1051-0443(95)71198-8 contributor: fullname: EC Martin – volume: 19 start-page: 155 year: 1993 ident: 2429_CR22 publication-title: Semin Thromb Hemost contributor: fullname: KM Schmid – volume: 9 start-page: 44 issue: Suppl 1 year: 1995 ident: 2429_CR10 publication-title: Fibrinolysis doi: 10.1016/S0268-9499(05)80010-4 contributor: fullname: CC Haudenschild – volume: 265 start-page: 625 year: 1977 ident: 2429_CR14 publication-title: Nature doi: 10.1038/265625a0 contributor: fullname: AW Clowes – ident: 2429_CR23 – volume: 3 start-page: 369 year: 1996 ident: 2429_CR25 publication-title: J Endovasc Surg doi: 10.1583/1074-6218(1996)003<0369:CEWANN>2.0.CO;2 contributor: fullname: M Henry – volume: 20 start-page: 207 year: 1991 ident: 2429_CR15 publication-title: Vasa contributor: fullname: H Hämmerle – volume: 117 start-page: 777 year: 1989 ident: 2429_CR16 publication-title: Am Heart J doi: 10.1016/0002-8703(89)90612-1 contributor: fullname: SG Ellis – volume: 91 start-page: 1676 year: 1995 ident: 2429_CR28 publication-title: Circulation doi: 10.1161/01.CIR.91.6.1676 contributor: fullname: A Colombo – volume: 68 start-page: 294 year: 1990 ident: 2429_CR19 publication-title: Klin Wochenschr doi: 10.1007/BF02116062 contributor: fullname: T Schmidt – ident: 2429_CR12 – ident: 2429_CR20 – volume: 85 start-page: 1548 year: 1992 ident: 2429_CR3 publication-title: Circulation doi: 10.1161/01.CIR.85.4.1548 contributor: fullname: H Hanke – volume: 74 start-page: 10 year: 1979 ident: 2429_CR2 publication-title: Basic Res Cardiol doi: 10.1007/BF01907681 contributor: fullname: E Betz – volume: 205 start-page: 375 year: 1997 ident: 2429_CR9 publication-title: Radiology doi: 10.1148/radiology.205.2.9356617 contributor: fullname: EP Strecker – volume: 314 start-page: 488 year: 1986 ident: 2429_CR11 publication-title: N Engl J Med doi: 10.1056/NEJM198602203140806 contributor: fullname: R Ross – volume: 20 start-page: 70 year: 1996 ident: 2429_CR26 publication-title: Cardiovasc Intervent Radiol contributor: fullname: E Starck – volume: 35 start-page: 125 issue: Suppl year: 1992 ident: 2429_CR21 publication-title: Vasa contributor: fullname: D Roth – volume: 2 start-page: 169 year: 1991 ident: 2429_CR5 publication-title: J Vasc Interv Radiol doi: 10.1016/S1051-0443(91)72275-6 contributor: fullname: RB Rutherford – volume: 67 start-page: 651 year: 1990 ident: 2429_CR13 publication-title: Circ Res doi: 10.1161/01.RES.67.3.651 contributor: fullname: H Hanke – volume: 94 start-page: 35 year: 1996 ident: 2429_CR27 publication-title: Circulation doi: 10.1161/01.CIR.94.1.35 contributor: fullname: GS Mintz – volume: 196 start-page: 167 year: 1995 ident: 2429_CR6 publication-title: Radiology doi: 10.1148/radiology.197.1.7568818 contributor: fullname: M Henry |
SSID | ssj0015825 |
Score | 1.6490047 |
Snippet | To examine the efficacy of the low-molecular-weight heparin, reviparin, for prevention of femoropopliteal stent restenosis.
Forty-two patients who had... Purpose: To examine the efficacy of the low-molecular-weight heparin, reviparin, for prevention of femoropopliteal stent restenosis.Methods: Forty-two patients... PURPOSETo examine the efficacy of the low-molecular-weight heparin, reviparin, for prevention of femoropopliteal stent restenosis.METHODSForty-two patients who... Purpose: To examine the efficacy of the low-molecular-weight heparin, reviparin, for prevention of femoropopliteal stent restenosis. Methods: Forty-two... |
SourceID | osti proquest crossref pubmed pascalfrancis |
SourceType | Open Access Repository Aggregation Database Index Database |
StartPage | 375 |
SubjectTerms | ACETYLSALICYLIC ACID Adult Aged Aged, 80 and over Angiography Angioplasty Angioplasty, Balloon - adverse effects Ankle Anticoagulants - administration & dosage Arterial Occlusive Diseases - drug therapy Arterial Occlusive Diseases - surgery ARTERIES Aspirin Biological and medical sciences BIOMEDICAL RADIOGRAPHY Complications Constriction, Pathologic - etiology Constriction, Pathologic - prevention & control Diseases of the cardiovascular system DOSES Female Femoral Vein - surgery Follow-Up Studies Hemorrhage HEPARIN Heparin, Low-Molecular-Weight - administration & dosage Humans Implantation Implants Male Medical imaging Medical sciences Middle Aged MOLECULAR WEIGHT Occlusion PATIENTS Popliteal Vein - surgery Postoperative Period Premedication Preoperative Care Prospective Studies RADIOLOGY AND NUCLEAR MEDICINE Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects) Restenosis Secondary Prevention Stents Stents - adverse effects Surgical implants SYMPTOMS TANTALUM Thromboembolism Treatment Outcome Vascular Patency - drug effects Weight reduction |
Title | Low-molecular-weight heparin (reviparin) reduces the incidence of femoropopliteal in-stent stenosis : Preliminary results of an ongoing study |
URI | https://www.ncbi.nlm.nih.gov/pubmed/9853142 https://www.proquest.com/docview/728413415/abstract/ https://search.proquest.com/docview/70116775 https://www.osti.gov/biblio/21080370 |
Volume | 21 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1baxQxFA7tLogv4q24tl3zIKIPYWeSTNLxRbrStYhdiljYtyGTTWqhTtadWYr_wR_tOZkL9kFfhoFJMpCTnHw5t4-Q19J4Z51MmFXWMaQoZCVmo0ljuBXcn8hYvvhiqc6v5OdVttojn_pcGAyr7HViVNTrYNFGPtOgR7H4WDYzJRoBbDP7sPnJkD4K3awdl8Y-GfNUor92PD9bXn4dHArZCW-jGbVkiBK6cpsxiw6vZugfwqP23vE0CrDNMFrS1DBhvmW6-DcUjUfS4jF51GFJetoK_wnZc9VT8uCi85Y_I7-_hDv2o-e_ZXfRCkq_OyQerOhbDPCNr-_oFgu4upoCGqRofI9EozR46jEQN2zCBlOV4V83FYNlUTUUn6G-qd_Ty627jdRg218wTr27bWrsaSoaqusAJyONJWyfk6vF2beP56xjX2BWaN6wNSiDNBXacgBlgq9zATdHXaLnLvFGlV4apwHt5B5UlFHKKaFMkkfGTS61FgdkVIXKvSBUWpWXCi53iUulLz1csXInnUwtaIvMpRPypp_0YtMW2SiGcsp_S2dCjlAkBaADLHFrMRbINgXHQEmhkwk5vieqYTAuhcgUdD_sRVd0W7UuhoU1Ia-Gr7DH0HFiKhd20CR6qzS0OGjlPQycA9pJJX_534EPycM2kxEj047IqNnu3DFAmaackn290lMyPl3M58tpt2j_AEi09OU |
link.rule.ids | 230,315,786,790,891,12083,21416,27957,27958,31754,31755,33779,33780,43345,43840,74102,74659 |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3BbtQwELXKVgIuiAIVS1vqA6rgYJHYjt30UiFEtYXdqodW2lvkeO1SqdjLJquKf-CjmXGyET3AJYqUxJE89viN53keIe-k8c46mTGrrGMoUchqPI0mjeFWcH8sU_ni2YWaXMuv82Lec3Oanla58YnJUS-ixT3yjxr8KBYfK06XPxmKRmFytVfQeES2pRASGX16PsRbeXHMOwajlgyRQV9iM52cw3AMc0K4vD5YkkYRphYyJE0DneQ7dYt_w8-0DJ09J896_Eg_dQbfIVsuvCCPZ32G_CX5PY337MdG85bdp51P-t2h2GCg75HUm24_0BUWbXUNBQRIccM9iYvS6KlH8m1cxiUeT4Z_3QYGQyG0FK-xuW1O6OXK3SU5sNUvaKdZ37UNfmkCjeEmwmpIU9naV-T67MvV5wnrFReYFZq3bAEOIM-FthyAmOCLUkC0qGvM1mXeqNpL4zQgnNKDWzJKOSWUycqkssml1mKXjEIM7jWh0qqyVhDQZS6XvvYQVpVOOplb8BCFy8fkaNPp1bIrrFENJZT_ts6Y7KNJKkAEWNbWIv_HthVHcqTQ2ZgcPDDV0BiHIVEo-HxvY7qqn55NNQymMTkcnsK8wmSJCS6u4ZWUodLwxm5n76HhEhBOLvmb_zZ8SJ5MrmbTanp-8W2PPO1OMiIzbZ-M2tXaHQCUaeu3acD-AbWH8E8 |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Nb9QwELVgkSouiK-KpS31ASE4WE1sx264IASsCrRVD1TaW-R47VKp2NtNVlX_Az-aGccb0QNcVpE2caSMPfPGM36PkNfSeGedLJhV1jGUKGQtnkaTxnAruD-Uib745FQdnctv82qeKYW63Fa58YnJUS-ixT3yAw1-FMnHqgOfuyLOPs8-LK8ZCkhhoTWradwnDyBIFihmoOdj7lVWh3zoZtSSIUrIdJvpFB2mZlgfwlB7JzxNIiwz7JY0HXwwPyhd_BuKppA0e0weZSxJPw7Gf0LuufCUbJ3kavkz8vs43rBfG_1bdpN2QelPh8KDgb7FBt90-Y6ukMDVdRTQIMXN9yQ0SqOnHhtx4zIu8agyvOsyMJgWoaf4G7vL7j09W7mrJA22uoVxuvVV3-GTJtAYLiJERpoobJ-T89mXH5-OWFZfYFZo3rMFOIOyFNpyAGWCL2oBmaNusXJXeKNaL43TgHZqDy7KKOWUUKaok-Iml1qLbTIJMbgXhEqr6lZBcle4UvrWQ4pVO-lkacFbVK6ckjebj94sB5KNZqRT_ts6U7KLJmkAHSDFrcVeINs3HBslhS6mZO-OqcbBuBSiUvD4zsZ0TV6qXTNOrCnZH_-FNYaFExNcXMMtqVql4Y7twd7jwDWgnVLyl_8deJ9swVxtjr-eft8hD4dDjdiktksm_Wrt9gDV9O2rNF__AOwE9Hs |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Low-molecular-weight+heparin+%28reviparin%29+reduces+the+incidence+of+femoropopliteal+in-stent+stenosis%3A+preliminary+results+of+an+ongoing+study&rft.jtitle=Cardiovascular+and+interventional+radiology&rft.au=Strecker%2C+E+P&rft.au=G%C3%B6ttmann%2C+D&rft.au=Boos%2C+I+B&rft.au=Vetter%2C+S&rft.date=1998-09-01&rft.issn=0174-1551&rft.eissn=1432-086X&rft.volume=21&rft.issue=5&rft.spage=375&rft_id=info:doi/10.1007%2Fs002709900283&rft_id=info%3Apmid%2F9853142&rft.externalDocID=9853142 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0174-1551&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0174-1551&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0174-1551&client=summon |